U.S. Physical Therapy, Inc. cash flow to debt ratio of 17.63% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

U.S. Physical Therapy, Inc.'s free cash flow has decreased 7.25% from $65.75M last year to $60.99M, signaling decreasing performance

U.S. Physical Therapy, Inc.'s debt to equity ratio is 0.38, which means that the company's assets are healthy financed, signaling financial stability.

U.S. Physical Therapy, Inc.'s debt has decreased relative to shareholder equity from 0.60 last year to 0.38 today, signaling strengthened financials

U.S. Physical Therapy, Inc. has a net debt to EBITDA ratio of 3.56x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

U.S. Physical Therapy, Inc.'s interest coverage ratio of 7.83 indicates that earnings with good margin can cover interest payments on company debt

U.S. Physical Therapy, Inc.'s profit margin has decreased (92.63%) in the last year from 3.94% to 0.29%, signaling decreasing performance

U.S. Physical Therapy, Inc.'s short-term assets of $139.99M exceed its short-term liabilities of $139.04M

U.S. Physical Therapy, Inc.'s return on assets of 0.18% is lower than the 5.00% threshold, indicating inefficient asset utilization

U.S. Physical Therapy, Inc.'s return on equity of 0.48%, is lower than 15.00%, indicating bad performance

U.S. Physical Therapy, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

U.S. Physical Therapy, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

U.S. Physical Therapy, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

U.S. Physical Therapy, Inc. has a free cash flow yield of 4.90%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

U.S. Physical Therapy, Inc.'s yearly earnings has decreased 43.08% since last year from $26.46M to $15.06M, signaling decreasing performance

U.S. Physical Therapy, Inc.'s yearly revenue has increased 16.33% since last year from $671.35M to $780.99M, signaling increasing performance

ROIC 5.25% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

U.S. Physical Therapy, Inc.'s 3-year revenue CAGR of 12.19% is positive, indicating growing revenue over the past 3 years

U.S. Physical Therapy, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

U.S. Physical Therapy, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

U.S. Physical Therapy, Inc. is overvalued relative to its fair value price of 7.44 based on Discounted Cash Flow model

U.S. Physical Therapy, Inc. has an earnings yield of 0.18%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

U.S. Physical Therapy, Inc. is overvalued relative to its fair value price of 24.83 based on EBITDA multiple model

U.S. Physical Therapy, Inc. has an EV/EBITDA ratio of 14.90x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

U.S. Physical Therapy, Inc. is undervalued relative to its fair value price of 99.56 based on Earnings Fair Value model

U.S. Physical Therapy, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

U.S. Physical Therapy, Inc. has a price-to-book ratio of 1.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

U.S. Physical Therapy, Inc. has a price-to-sales ratio of 1.58x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue